Funding Support and Author Disclosures Dr Kramer has served as a consultant for Eli Lilly and Co; and has received research grant support from Eli Lilly and Co, Bristol Myers Squibb, and Cytokinetics. Dr Borlaug has received research grant support from the National Institutes of Health and the U.S. Department of Defense, AstraZeneca, Axon, Corvia, Novo Nordisk, and Tenax Therapeutics; has served as a consultant for Actelion, Amgen, Aria, Axon Therapies, BD, Boehringer Ingelheim, Cytokinetics, Edwards Lifesciences, Lilly, Imbria, Janssen, Merck, Novo Nordisk, NGM, NXT, and VADovations; and is a named inventor (U.S. Patent No. 10,307,179) for the tools and approach for a minimally invasive pericardial modification procedure to treat heart failure. Dr Zile has received research support from the U.S. Department of Veterans Affairs (Project Nos. BX005943, BX005848); and has served as a consultant for Abbott, Adona Medical, Aria CV, Avery Therapeutics, Boehringer Ingelheim, Boston Scientific, Cardiovascular Research Foundation Clinical Trials Center, CVRx, DIASTOL Therapeutics, EBR, Edwards, Lilly, GenKardia, Innoventric, KestraMedical, Medtronic, Merck, Morphic Therapeutics, Novartis, Pulnova, Salubris Biotherapeutics, Sonata, SRNALYTICS, V-WAVE, and Vectorious. Dr Ruff, Dr Ou, Ms Hurt, and Dr Murakami are employees of Eli Lilly and Co. Dr Packer has served as a consultant for 89bio, AbbVie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Lilly, Imara, Medtronic, Moderna, Novartis, Pharmacocosmos, Reata, Regeneron, Roche, and Salamandra. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
PubMed
